U.S. markets close in 2 hours 10 minutes
  • S&P 500

    4,531.30
    +11.67 (+0.26%)
     
  • Dow 30

    35,610.80
    +153.49 (+0.43%)
     
  • Nasdaq

    15,098.31
    -30.78 (-0.20%)
     
  • Russell 2000

    2,288.36
    +12.45 (+0.55%)
     
  • Crude Oil

    83.60
    +0.64 (+0.77%)
     
  • Gold

    1,785.60
    +15.10 (+0.85%)
     
  • Silver

    24.42
    +0.54 (+2.27%)
     
  • EUR/USD

    1.1660
    +0.0023 (+0.20%)
     
  • 10-Yr Bond

    1.6460
    +0.0110 (+0.67%)
     
  • GBP/USD

    1.3820
    +0.0026 (+0.19%)
     
  • USD/JPY

    114.2100
    -0.1500 (-0.13%)
     
  • BTC-USD

    66,397.10
    +3,102.11 (+4.90%)
     
  • CMC Crypto 200

    1,545.42
    +64.61 (+4.36%)
     
  • FTSE 100

    7,223.10
    +5.57 (+0.08%)
     
  • Nikkei 225

    29,255.55
    +40.03 (+0.14%)
     

Recro Pharma- "Absurdly Cheap"

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Recently, Recro Pharma (REPH) reported earnings and issued weak guidance for 2020. In 2019, REPH benefited as it manufactures a product called Verapamil for Teva Pharmaceutical Industries (TEVA), notes Rich Howe, editor of Stock Spin-Off Newsletter.

More from Rich Howe: Spin-Off Expert Eyes 3 Ways to Win With Recro Pharma

Verapamil is a calcium channel blocker; demand was very strong in 2019 as Mylan (MYL), who also manufactured the product, was out of the market due to quality control issues at its plant.

REPH expects Mylan to come back to market and as a result, expects some destocking from Teva. This will be a revenue headwind.

However, REPH also expects significant growth from its business development efforts which will offset the destocking. As a result, revenue and its contract developing and manufacturing organization (CDMO) segment EBITDA is expected to be roughly flat.

I think management is being very conservative with guidance. Historically, actual revenue has been 10% to 25% higher than initial guidance dating from 2016 to 2019. Further, REPH is trading at 7.2x ‘20 EBITDA and 13.9x ‘20 EPS.

See also: Crown Castle: A Low Beta Buy

Seems absurdly cheap for a high quality, defensive business in a consolidating industry where peers are being acquired for 16.0x EBITDA.

While guidance was indeed disappointing, my investment case for REPH is very much intact. I believe guidance is very conservative, and the long term outlook for the business remains healthy. I took advantage of the recent weakness and bought some more of REPH in the mid $10 range.

More From MoneyShow.com: